Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 951361, 7 pages
http://dx.doi.org/10.1155/2015/951361
Research Article

Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A

1State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau
2Institute of New Drug Research, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine & New Drug Research, College of Pharmacy, Jinan University, Guangdong, China

Received 9 February 2015; Revised 14 April 2015; Accepted 15 April 2015

Academic Editor: Antonio Pisani

Copyright © 2015 Fei Sa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Rodriguez-Pallares, J. A. Parga, A. Muñoz, P. Rey, M. J. Guerra, and J. L. Labandeira-Garcia, “Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons,” Journal of Neurochemistry, vol. 103, no. 1, pp. 145–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. J. Zhang, W. Cui, G. H. Li et al., “Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCα and PI3K/AKT signaling pathways,” Journal of Agricultural and Food Chemistry, vol. 60, no. 33, pp. 8171–8182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. J. Zhang, L. C. V. Cheang, M. W. Wang, and S. M.-Y. Lee, “Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish,” International Journal of Molecular Medicine, vol. 27, no. 2, pp. 195–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Cui, Z. Zhang, W. Li et al., “Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase,” PLoS ONE, vol. 7, no. 9, Article ID e46253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Xu, H. Duan, Z. Zhang et al., “The novel tetramethylpyrazine bis-nitrone (TN-2) protects against MPTP/MPP+-induced neurotoxicity via inhibition of mitochondrial-dependent apoptosis,” Journal of Neuroimmune Pharmacology, vol. 9, no. 2, pp. 245–258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Ci, R. Ren, K. Xu et al., “Schisantherin a exhibits anti-inflammatory properties by down-regulating NF-κB and MAPK signaling pathways in lipopolysaccharide-treated RAW 264.7 cells,” Inflammation, vol. 33, no. 2, pp. 126–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Chang, Y. Li, X. Yang et al., “Protective role of deoxyschizandrin and schisantherin A against myocardial ischemia-reperfusion injury in rats,” PLoS ONE, vol. 8, no. 4, Article ID e61590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Liu, Y.-F. Cao, Z.-Z. Fang et al., “Strong inhibition of deoxyschizandrin and schisantherin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based herb-drug interaction,” Fitoterapia, vol. 83, no. 8, pp. 1415–1419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Sa, L. Q. Zhang, C. M. Chong et al., “Discovery of novel anti-Parkinsonian effect of schisantherin A in in vitro and in vivo,” Neuroscience Letters, vol. 593, pp. 7–12, 2015. View at Publisher · View at Google Scholar
  10. L. Q. Zhang, F. Sa, C. M. Chong et al., “Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and Akt/GSK3β pathways,” Journal of Enthopharmacology. In press.
  11. A. H. Schapira, C. W. Olanow, J. T. Greenamyre, and E. Bezard, “Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives,” The Lancet, vol. 384, no. 9942, pp. 545–555, 2014. View at Publisher · View at Google Scholar
  12. M. Xu, G. Wang, H. Xie et al., “Determination of schizandrin in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 828, no. 1-2, pp. 55–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. E. Müller, “Prodrug approaches for enhancing the bioavailability of drugs with low solubility,” Chemistry & Biodiversity, vol. 6, no. 11, pp. 2071–2083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Mitragotri, P. A. Burke, and R. Langer, “Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies,” Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 655–672, 2014. View at Publisher · View at Google Scholar
  15. B. Biruss and C. Valenta, “The advantage of polymer addition to a non-ionic oil in water microemulsion for the dermal delivery of progesterone,” International Journal of Pharmaceutics, vol. 349, no. 1-2, pp. 269–273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Prakash, K. Chopra, and B. Medhi, “Granulocyte-colony stimulating factor improves Parkinson's disease associated with co-morbid depression: an experimental exploratory study,” Indian Journal of Pharmacology, vol. 45, no. 6, pp. 612–615, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. F. F. Campos, A. C. Calpena Campmany, G. R. Delgado, O. L. Serrano, and B. C. Naveros, “Development and characterization of a novel nystatin-loaded nanoemulsion for the buccal treatment of candidosis: ultrastructural effects and release studies,” Journal of Pharmaceutical Sciences, vol. 101, no. 10, pp. 3739–3752, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Pei, Q. Lv, J. Han et al., “Schisandra lignans-loaded enteric nanoparticles: preparation, characterization, and in vitro-in vivo evaluation,” Journal of Drug Targeting, vol. 21, no. 2, pp. 180–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Gunasekaran, T. Haile, T. Nigusse, and M. D. Dhanaraju, “Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine,” Asian Pacific Journal of Tropical Biomedicine, vol. 4, supplement 1, pp. S1–S7, 2014. View at Publisher · View at Google Scholar
  20. T. Gershanik, E. Haltner, C.-M. Lehr, and S. Benita, “Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity,” International Journal of Pharmaceutics, vol. 211, no. 1-2, pp. 29–36, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Xu, R. Ni, W. Sun, L. C. Li, and S. Mao, “In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative,” Drug Development and Industrial Pharmacy, vol. 41, no. 4, pp. 552–559, 2015. View at Publisher · View at Google Scholar
  22. R. Pangeni, S. Sharma, G. Mustafa, J. Ali, and S. Baboota, “Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress,” Nanotechnology, vol. 25, no. 48, Article ID 485102, 2014. View at Publisher · View at Google Scholar
  23. M. Sessa, M. L. Balestrieri, G. Ferrari et al., “Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems,” Food Chemistry, vol. 147, pp. 42–50, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Amri, S. Le Clanche, P. Thérond et al., “Resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 86, no. 3, pp. 418–426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Singh and R. S. Pai, “Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies,” Drug Delivery, 2014. View at Publisher · View at Google Scholar
  26. R. P. Joshi, G. Negi, A. Kumar et al., “SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 9, no. 6, pp. 776–785, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Wei, Q. Li, R. Fan et al., “UFLC-MS/MS method for simultaneous determination of six lignans of Schisandra chinensis (Turcz.) Baill. in normal and insomniac rats brain microdialysates and homogenate samples: towards an in-depth study for its sedative-hypnotic activity,” Journal of Mass Spectrometry, vol. 48, no. 4, pp. 448–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. B.-L. Wang, J.-P. Hu, L. Sheng, H. Chen, and Y. Li, “Chemical-pharmacokinetic-pharmacodynamic fingerprints of Schisandra chinensis alcoholic extract,” Yao Xue Xue Bao, vol. 48, no. 5, pp. 734–740, 2013. View at Google Scholar · View at Scopus